Reboxetine Treatment of Depression in Parkinson's Disease
J Clin Psychiatry 2000;61(11):872 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: The efficacy and tolerability of reboxetine, a norepinephrine reuptake inhibitor, have been shown in patients with major depressive disorder or dysthymia. This novel antidepressant shows negligible effects on psychomotor and cognitive function and may be especially effective in improving negative self-perception and lack of motivation toward action. Depression occurs frequently in Parkinson’s disease and appears to be associated with greater frontal lobe dysfunctions, including reward and motivational systems, and greater involvement of dopaminergic and noradrenergic systems than in nondepressed Parkinson’s patients. We report for the first time reboxetine treatment of depression in Parkinson’s disease after prior treatment with amitriptyline and fluoxetine was ineffective and accompanied by intolerable side effects.